Drugs / HLD100
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02884544 | Aug → Dec 2016 | attention deficit-hyperactivity disorder | Ironshore Pharmaceuticals and Development, Inc | Completed | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HLD100 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02884544 ↗ |